AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9927843 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment
Number of subjects: 0
Study 8601041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mannitol (50 g) and albumin (75 g) in the pump prime
Number of subjects: 103
Study 8601041 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 103
Study 2632375 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianxiety drug
Number of subjects: 48
Study 2632375 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 48
Study 2632375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2632375 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 48
Study 4925514 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarials
Number of subjects: 0
Study 4925514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31980899 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-oriented resilience therapy (BEATVIC)
Number of subjects: 27
Study 31980899 — intervention group
Group type: COMPARATOR
Intervention: Befriending (Control)
Number of subjects: 27
Study 30476940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intraperitoneal mesh implantation
Number of subjects: 150
Study 30476940 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal closure
Number of subjects: 150
Study 27301484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrategy childcare-based intervention including staff training, resources, audit and feedback, ongoing support, and securing executive support.
Number of subjects: 58
Study 27301484 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 58
Study 27301484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrategy childcare-based intervention
Number of subjects: 58
Study 27301484 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 58
Study 24602409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 162
Study 24602409 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 162
Study 24602409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 22821414 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous distal metatarsal osteotomy
Number of subjects: 64
Study 22821414 — intervention group
Group type: COMPARATOR
Intervention: Distal chevron osteotomy
Number of subjects: 64
Study 20537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine group (l‐glutamine 0.4g/[kg d])
Number of subjects: 30
Study 20537501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 20537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine group
Number of subjects: 30
Study 18544001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole (200 mg single dose)
Number of subjects: 41
Study 18544001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily on day 1, then 3 mg/kg twice daily from days 2-6, followed by 3 mg/kg on day 7)
Number of subjects: 41
Study 18544001 — intervention group
Group type: COMPARATOR
Intervention: Intravenous voriconazole solubilized with SBECD
Number of subjects: 41
Study 15752161 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion followed by platelet concentrates (PCs)
Number of subjects: 10
Study 15752161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12625491 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 2493
Study 12625491 — intervention group
Group type: COMPARATOR
Intervention: No Coronary Angiography (No CA)
Number of subjects: 2493
Study 9758088 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14400
Study 9758088 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 14400
Study 1929272 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg daily
Number of subjects: 102
Study 1929272 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin 50 mg daily
Number of subjects: 102
Study 6800439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin with sodium glycocholate
Number of subjects: 7
Study 6800439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 7
Study 6800439 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 7
Study 6800439 — intervention group
Group type: COMPARATOR
Intervention: Intravenous insulin
Number of subjects: 7
Study 30977081 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized dynamic posturography (CDP) training, optokinetic stimulus, or exercise at home
Number of subjects: 57
Study 31530577 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 31530577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 28591282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 35
Study 28591282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 35
Study 28591282 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 35
Study 28591282 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 35
Study 27062270 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d)
Number of subjects: 32
Study 27062270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24442886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous zoledronate
Number of subjects: 100
Study 22435747 — intervention group
Group type: EXPERIMENTAL
Intervention: G+P (Granulocyte colony-stimulating factor with plerixafor)
Number of subjects: 0
Study 22435747 — intervention group
Group type: COMPARATOR
Intervention: G-CSF (Granulocyte colony-stimulating factor)
Number of subjects: 0
Study 18981719 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before treatment
Number of subjects: 120
Study 18981719 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care (no epoetin beta)
Number of subjects: 120
Study 17670860 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 days ULLS+RE
Number of subjects: 48
Study 17670860 — intervention group
Group type: COMPARATOR
Intervention: 35 days ULLS
Number of subjects: 48
Study 17670860 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 days BR+RE
Number of subjects: 48
Study 17670860 — intervention group
Group type: COMPARATOR
Intervention: 90 days BR
Number of subjects: 48
Study 15197670 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 of 0.5 with CPAP (OLV-CPAP)
Number of subjects: 20
Study 15197670 — intervention group
Group type: COMPARATOR
Intervention: FiO2 of 1.0 without CPAP (OLV-100)
Number of subjects: 20
Study 11233804 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g i.v. every 8 hours
Number of subjects: 140
Study 11233804 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every 8 hours plus Amikacin 15 mg/kg daily
Number of subjects: 140
Study 11233804 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 140
Study 11233804 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/Amikacin
Number of subjects: 140
Study 9850361 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (0, 200, 400 or 800 micrograms day-1)
Number of subjects: 43
Study 9850361 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (800 micrograms day-1)
Number of subjects: 43
Study 9850361 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (400 micrograms day-1)
Number of subjects: 43
Study 9850361 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (1500 micrograms day-1)
Number of subjects: 43
Study 9850361 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (up to 800 micrograms day-1)
Number of subjects: 43
Study 9850361 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP
Number of subjects: 43
Study 7501332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal PGE2 gel (2 mg)
Number of subjects: 200
Study 7501332 — intervention group
Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (3 mg)
Number of subjects: 200
Study 2169703 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol supplementation (1000 mg Ca/d and 1000 IU cholecalciferol/d)
Number of subjects: 65
Study 2169703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7214297 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy for periods of 9.4 +/- 1.7 months
Number of subjects: 20
Study 7214297 — intervention group
Group type: COMPARATOR
Intervention: No BCG immunotherapy (control group)
Number of subjects: 20
Study 7214297 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Diseases (CVD) prevalence
Number of subjects: 12338
Study 31529935 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with CVD
Number of subjects: 12338
Study 28327694 — intervention group
Group type: EXPERIMENTAL
Intervention: SurfLink-treated titanium dental implants
Number of subjects: 23
Study 28327694 — intervention group
Group type: COMPARATOR
Intervention: Untreated control titanium dental implants
Number of subjects: 23
Study 28327694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SurfLink and control implants
Number of subjects: 23
Study 26318757 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy using oesophageal Doppler during surgery
Number of subjects: 0
Study 24371255 — intervention group
Group type: EXPERIMENTAL
Intervention: A(H3N2) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Number of subjects: 43000
Study 24371255 — intervention group
Group type: EXPERIMENTAL
Intervention: A(H1N1) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Number of subjects: 43000
Study 24371255 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR subtyping for A(H3N2) and A(H1N1) viruses
Number of subjects: 43000
Study 24371255 — intervention group
Group type: EXPERIMENTAL
Intervention: HA1 sequence analysis
Number of subjects: 43000
Study 22555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary program of geriatric consultation, in-hospital and at-home rehabilitation, and discharge planning (n = 80)
Number of subjects: 162
Study 22555886 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 82)
Number of subjects: 162
Study 20011757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrice (NaF dentifrice) on a toothbrush for 60 s twice a day
Number of subjects: 32
Study 20011757 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwaxed dental floss twice a day
Number of subjects: 32
Study 20011757 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxed dental floss twice a day in every interproximal space
Number of subjects: 32
Study 20011757 — intervention group
Group type: COMPARATOR
Intervention: Drinking water rinsing twice a day for 60 s
Number of subjects: 32
Study 17142825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 u of oxytocin as a bolus injection
Number of subjects: 30
Study 17142825 — intervention group
Group type: COMPARATOR
Intervention: 5 u of oxytocin as an infusion over 5 min
Number of subjects: 30
Study 17142825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bolus and infusion)
Number of subjects: 30
Study 15107384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three)
Number of subjects: 0
Study 15107384 — intervention group
Group type: COMPARATOR
Intervention: Cautious dosing regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg)
Number of subjects: 0
Study 15107384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dosing regimen
Number of subjects: 0
Study 15107384 — intervention group
Group type: COMPARATOR
Intervention: Cautious dosing regimen
Number of subjects: 0
Study 11454114 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 28
Study 11454114 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 28
Study 9630259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (treatment for 4 months)
Number of subjects: 30
Study 9630259 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (4 months without treatment followed by 4 months of treatment)
Number of subjects: 30
Study 8001718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol solutions
Number of subjects: 0
Study 8001718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol chocolate
Number of subjects: 0
Study 8001718 — intervention group
Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 0
Study 8001718 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 0
Study 8001718 — intervention group
Group type: COMPARATOR
Intervention: Sucrose containing chocolate (control)
Number of subjects: 0
Study 2220638 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 46
Study 2220638 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 46
Study 671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at theoretically appropriate locations
Number of subjects: 0
Study 671428 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at theoretically inappropriate locations
Number of subjects: 0
Study 31819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling using candidate gene specific primers (14 candidate genes, 12 reported and 14 designed primer pairs)
Number of subjects: 28
Study 31819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Single marker analysis
Number of subjects: 28
Study 31819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular analysis based on candidate genes specific primers
Number of subjects: 28
Study 31819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical classification and principal co‐ordinate analysis
Number of subjects: 28
Study 26489973 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Rotational Atherectomy (RA)
Number of subjects: 198
Study 26489973 — intervention group
Group type: COMPARATOR
Intervention: Delayed Rotational Atherectomy (RA)
Number of subjects: 198
Study 23821328 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboRT (carboplatin 100 mg/m2)
Number of subjects: 51
Study 23821328 — intervention group
Group type: COMPARATOR
Intervention: CisRT (cisplatin 40 mg/m2)
Number of subjects: 51
Study 22112202 — intervention group
Group type: EXPERIMENTAL
Intervention: 36‐ingredient micronutrient formula (mainly vitamins and minerals) consumed over an 8‐week period
Number of subjects: 14
Study 22112202 — intervention group
Group type: COMPARATOR
Intervention: Control group of 14 non‐ADHD adults not taking the formula
Number of subjects: 14
Study 19125120 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25[OH]D) concentration
Number of subjects: 29
Study 19125120 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal symptoms (muscle pain in neck and back)
Number of subjects: 29
Study 17091139 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 (IntenS with hard polymerization)
Number of subjects: 14
Study 17091139 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 (IntenS with soft polymerization)
Number of subjects: 14
Study 17091139 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 (Filtek flow)
Number of subjects: 14
Study 17091139 — intervention group
Group type: EXPERIMENTAL
Intervention: G4 (Fuji II LC)
Number of subjects: 14
Study 17091139 — intervention group
Group type: COMPARATOR
Intervention: G1, G2, G3
Number of subjects: 14
Study 17091139 — intervention group
Group type: COMPARATOR
Intervention: G1=G2
Number of subjects: 14
Study 17091139 — intervention group
Group type: COMPARATOR
Intervention: G1=G2=G3
Number of subjects: 14
Study 14751362 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (estramustine 140 mg three times daily and etoposide 100 mg orally for 21 days)
Number of subjects: 40
Study 14751362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of somatostatin analog (lanreotide 30 mg intramuscularly every 14 days) and dexamethasone (4 mg tapered to 1 mg)
Number of subjects: 40
Study 14751362 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40
Study 14751362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 40
Study 11599647 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine daily
Number of subjects: 70
Study 11599647 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of fluoxetine weekly
Number of subjects: 70
Study 11599647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 37
Study 15613168 — intervention group
Group type: COMPARATOR
Intervention: Desipramine 75 mg
Number of subjects: 37
Study 7929683 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic inventories of children with phonological delays
Number of subjects: 30
Study 7929683 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonetic inventories of children with phonological delays
Number of subjects: 30
Study 7929683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional results
Number of subjects: 30
Study 7929683 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical implications of phonemic acquisition
Number of subjects: 30
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the antecubital fossa with flushing after thiopentone
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the antecubital fossa without flushing
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the dorsum of the hand without flushing
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium maintained at room temperature for at least 2 weeks
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients with drug allergy)
Number of subjects: 150
Study 2974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients aged over 70 years)
Number of subjects: 150
Study 5328328 — intervention group
Group type: EXPERIMENTAL
Intervention: quinethazone 50 mg
Number of subjects: 27
Study 5328328 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorothiazide 500 mg
Number of subjects: 27
Study 5328328 — intervention group
Group type: COMPARATOR
Intervention: lactose placebo
Number of subjects: 27
Study 31912268 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser hemorrhoidoplasty (LHP)
Number of subjects: 121
Study 31912268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured mucopexy (MP)
Number of subjects: 121
Study 31912268 — intervention group
Group type: COMPARATOR
Intervention: Excisional hemorrhoidectomy (EH)
Number of subjects: 121
Study 29762642 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 152
Study 29762642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Number of subjects: 152
Study 28238301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase agkistrodon (n=48)
Number of subjects: 96
Study 28238301 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n=48)
Number of subjects: 96
Study 25264753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg)
Number of subjects: 25
Study 23450513 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sildenafil, 3 times per day for 9 weeks
Number of subjects: 70
Study 23450513 — intervention group
Group type: COMPARATOR
Intervention: Comparable placebo
Number of subjects: 70
Study 21276190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua sha
Number of subjects: 48
Study 21276190 — intervention group
Group type: COMPARATOR
Intervention: Control (local thermal heat pad)
Number of subjects: 48
Study 19076108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin + Dexamethasone
Number of subjects: 116
Study 19076108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin
Number of subjects: 116
Study 19076108 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol + Placebo
Number of subjects: 116
Study 16757158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once a day for 5 days
Number of subjects: 10
Study 16757158 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study 15522707 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with myotonic dystrophy (MD)
Number of subjects: 0
Study 15522707 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0